It will be important to determine whether the Rtt101 E3 human equivalent, Cullin-Ring-Ligase 4 (CRL4), also contributes to rNMP repair in RNase H2 defective cells, as this may represent alternative therapeutic opportunities, in addition to PARP inhibitors in RER defective cancer cells. This evidence concerns the gene IL17RB and cancer.